ELI LILLY & Co — Director's Dealing 2020

Dec 4, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Sigilon Therapeutics, Inc. (SGTX)
CIK: 0001821323
Period of Report: 2020-12-03

Reporting Person: ELI LILLY & Co (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A-3 Convertible Preferred Stock	$		Common Stock (1555555.0)		Direct
Series B Convertible Preferred Stock	$		Common Stock (888888.0)		Direct

Footnotes

F1: The Series A-3 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") is convertible into the number of shares of the Registrant's common stock shown in column 3 and has no expiration date. The Preferred Stock will automatically convert into common stock upon the closing of the Registrant's initial public offering.